Vancouver, B.C. – February 6, 2018 – Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced the appointment of industry veteran Dr. Kaiji Hu to its scientific team as Research Scientist - Cell and Molecular Biology. 

Vancouver, BC – December 6, 2017 -

Medipure Pharmaceuticals, a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced that they are further expanding both their corporate offices in Vancouver and their research labs in Burnaby, B.C., to enhance the Company’s research aimed at developing cannabinoid-derived molecules into non-addictive pharmaceutical drugs.

Medipure Pharmaceuticals Inc.: History and Developments

Every day, millions of people around the world suffer with chronic pain, anxiety and skin conditions, greatly affecting their quality of life. At Medipure Pharmaceuticals Inc., we believe that this suffering can be alleviated. That’s why we specialize in researching, developing, testing and marketing new pharmaceutical drugs aimed at reversing chronic pain/anxiety and skin conditions, as well as reducing both the elevated costs and unpredictable side effects of existing medication and techniques.

Dr. Andrea Furlan, Associate Professor of Medicine at the University of Toronto, commented recently that pain management is at the core of Canada’s opioid crisis and the key to a solution.

In an article originally published in "The Conversation", an independent and non-profit Academic Journal and reprinted in the National Post, Dr. Furlan noted that two people die every day in Ontario from an opioid overdose. The prevalence of opioids and the physician’s prescription notepad share the responsibility.